logo
logo

Safeheal Closes €40 Million Financing Co-Led By Sofinnova Partners And Genesis Medtech To Finance Its Colovac Device Through A Pivotal Clinical Trial In The United States

Jan 31, 2022•over 3 years ago

Amount Raised

€40 Million

Paris

Description

PARIS, FRANCE / January 31, 2022 / SafeHeal, a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today a successful 40M€ financing, co-led by Sofinnova Partners and Genesis MedTech Group. Sofinnova Partners is a leading venture capital firm based in Paris, London, and Milan and a historic shareholder in the company. Genesis MedTech is a medical device company headquartered in Singapore.

Company Information

Company

Safeheal

Location

Paris, Ile De France, France

About

SafeHeal is an early-stage medical device company in Paris and created in 2015. The company develops Colovac, a device invented by a French digestive surgeon, Dr. Charam Khosrovani, to obviate the need for a digestive ostomy in patients undergoing colorectal surgery. The device is a flexible bypass sheath, intended to reduce any contact of fecal content at the anastomotic level, following colorectal surgery. Colovac is seamless, minimally invasive, and fully reversible. The device remains in place for 10 days, after which it is removed during an endoscopic procedure, without the need for a second surgical intervention. This enables patients to resume their normal life without having to bear an artificial anus or stoma for several months. SafeHeal was founded by MD Start II.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech